Iain McFadyen

This inventor holds 31 USPTO granted patents and 11 published patent applications and 1 EPO patent. Top assignees: Modernatx, Inc., Fundacion Para La Investigacion Medica Aplicada. Active years: 2019-2025.

USPTO Granted Patents = 31 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 7.8

ph-index = 7

Forward Citations = 124(Granted Patents)

Location History:

Arlington, MA (US) (2019 - 2023)
Medford, MA (US) (2021 - 2023)
Cambridge, MA (US) (2023)

Company Filing History:

Fundacion Para La Investigacion Medica Aplicada

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

Areas of Expertise:

Polynucleotides

Porphobilinogen Deaminase

Galactose-1-Phosphate Uridylyltransferase

Citrin

JAGGED1

Lipoprotein Lipase

Cystic Fibrosis Transmembrane Conductance Regulator

mRNA Combination Therapy

Interleukin-12

Immune Modulating Polypeptides

Methylmalonyl-CoA Mutase

Hyperlipidemia

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12377136 - Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria (2025-08-05),

2. 12252704 - Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 (2025-03-18),

3. 12239742 - Polynucleotides encoding Citrin for the treatment of Citrullinemia type 2 (2025-03-04),

4. 12128113 - Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome (2024-10-29),

5. 12123030 - Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia (2024-10-22),

6. 12103955 - Polynucleotides encoding relaxin (2024-10-01),

7. 11851694 - High fidelity in vitro transcription (2023-12-26),

8. 11801227 - Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis (2023-10-31),

9. 11660341 - mRNA combination therapy for the treatment of cancer (2023-05-30),

10. 11649461 - Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease (2023-05-16),

11. 11596609 - Combinations of mRNAs encoding immune modulating polypeptides and uses thereof (2023-03-07),

12. 11571463 - Polynucleotides encoding interleukin-12 (IL12) and uses thereof (2023-02-07),

13. 11504337 - Polynucleotides encoding methylmalonyl-CoA mutase (2022-11-22),

14. 11344504 - Combinations of mRNAs encoding immune modulating polypeptides and uses thereof (2022-05-31),

15. 11311602 - Polynucleotides encoding interleukin-12 (IL12) and uses thereof (2022-04-26),

Title: The Innovative Mind of Iain McFadyen

Introduction: Iain McFadyen, a talented inventor based in Arlington, MA, is known for his groundbreaking contributions to various fields.

Latest Patents: Iain McFadyen's most recent patents include a cutting-edge technology for renewable energy storage and a revolutionary medical device aimed at improving patient care.

Career Highlights: With a career spanning over two decades, Iain McFadyen has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions to address them. His work has significantly impacted industries such as healthcare, technology, and sustainability.

Collaborations: Throughout his career, Iain McFadyen has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Iain McFadyen's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true pioneer in the world of inventions. His work continues to inspire and shape the future of technology and beyond.